Applied NeuroSolutions Hires Top Ranked Analyst, Ryan Rauch, to Direct its Investor Relations Program.

Former Head of Medical Technology / Diagnostics Equity Research Team at Jefferies and Various Other Investment Banks to Broaden Investor Awareness of APNS 

VERNON HILLS, Ill. -- Applied NeuroSolutions, Inc. (OTC BB:APNS)(www.appliedneurosolutions.com) a Company focused on the development of an integrated product portfolio for the treatment and diagnosis of Alzheimer's disease, today announced it has retained Ryan Rauch to expand its investor relations efforts. Mr. Rauch will work with Applied NeuroSolutions' management to develop and execute a comprehensive investor relations and communication program designed to enhance Applied NeuroSolutions visibility within the investment community.

Mr. Rauch has spent the past eleven plus years as a medical technology analyst, the past two years as a top ranked analyst at Jefferies & Company, while serving as the head of Jefferies' Medical Technology/Diagnostics Equity Research Team.

Ellen Hoffing, Applied NeuroSolutions' President and CEO said, "We are very excited to be working with Ryan Rauch, whose background and experience will provide key guidance in our ongoing communications with existing investors and support in reaching a broader audience."

Commenting on his appointment, Ryan Rauch said, "I look forward to working with Ellen Hoffing and the management team to build on APNS' long standing and supportive investor base, and to bring the strong APNS story to an expanded investment audience. The new therapeutic collaboration with Lilly and the novel work in Alzheimer's diagnostics, coupled with new management and Board members is a very compelling story that needs to be told."

About Applied NeuroSolutions:

Applied NeuroSolutions, Inc. (OTC BB:APNS) is developing, in collaboration with Eli Lilly and Company, novel therapeutic compounds to treat and diagnostics to detect Alzheimer's disease (AD) based on discoveries originating from the Albert Einstein College of Medicine. Applied NeuroSolutions has discovered biomarkers that the company believes will aid in the development of effective AD treatments. Applied NeuroSolutions has also been working on both a cerebrospinal fluid (CSF) test and a blood test to detect AD at a very early stage. The CSF test can already differentiate AD patients from those with other diseases that have similar symptoms. There is currently no FDA approved diagnostic test to detect Alzheimer's disease. Alzheimer's disease currently afflicts over 4 million Americans, and the market for AD therapy is expected to grow to 21 million patients by 2010 in the seven major pharmaceutical markets (USA, France, Germany, Italy, Spain, U.K. and Japan) according to BioPortfolio, Ltd. For more information, visit www.appliedneurosolutions.com.

This press release contains forward-looking statements about Applied NeuroSolutions. The company wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For further information, please visit the company's website at www.appliedneurosolutions.com, and review the company's filings with the Securities and Exchange Commission.